Participated · Series A · Nov 2023

Surglasses develops AR augmented reality surgical navigation systems and related products, solutions, and services to enhance healthcare intelligence. Its core product is the Caduceus S AR navigation system, an FDA 510(k)–cleared AR medical technology designed for complex spinal surgeries that overlays 3D spinal anatomy onto the patient via multiple trackers and a transparent head-mounted display. The company obtained Taiwan Class II medical device approval in 2022 and achieved FDA 510(k) clearance in the United States by the end of 2022. Led by CEO Miron Wang, Surglasses focuses on applications in orthopedics and neurosurgery. The company intends to use the funds to expand operations and development efforts, primarily to accelerate research, development, and promotion of Caduceus S. Surglasses is based in Taichung, Taiwan.